Lin Shen

Professor Lin Shen, Chief Physician, Professor, and Doctoral Supervisor, currently serves as Director of the Department of Gastrointestinal Oncology and Director of Phase I Clinical Trial Ward at Peking University Cancer Hospital, and is a member of the Beijing Municipal Committee of the Chinese People’s Political Consultative Conference. Previously served as Vice President of Peking University Cancer Hospital and Deputy Director of Beijing Cancer Prevention and Treatment Research Institute. Holds multiple important academic positions including inaugural Chairman of the Professional Committee on Clinical Research of Cancer Drugs of the Chinese Anti-Cancer Association, Chairman of the Professional Committee on Precision Cancer Treatment of the Chinese Anti-Cancer Association, and Chairman of the Expert Committee on Clinical Research of the Chinese Society of Clinical Oncology. Enjoys special government allowances from the State Council, has been honored with titles such as National Outstanding Science and Technology Worker and National March 8th Red-Banner Pacesetter, and has been selected as a “Beijing Scholar” and Beijing Outstanding Contribution Expert. Professor Shen Lin has long been committed to clinical and translational research on precision treatment of gastrointestinal tumors and new anti-cancer drugs. Major contributions include: establishing a clinical and translational research system for gastrointestinal tumors, which was selected for the China Association for Science and Technology’s “Innovation China” pioneering technology list; leading numerous new drug clinical studies and promoting the successful approval and marketing of new anti-cancer drugs. Has published nearly 200 SCI papers in international authoritative journals such as Nature, BMJ, Nature Medicine, and JCO, holds 10 national patents, and has edited/co-edited over 40 gastrointestinal tumor diagnosis and treatment guidelines. Research achievements have repeatedly won the Second Prize of National Science and Technology Progress Award, First Prize of Ministry of Education Science and Technology Progress Award, First Prize of Chinese Medical Science and Technology Award, First Prize of Chinese Anti-Cancer Association Science and Technology Award, and First and Second Prizes of Huaxia Medical Science and Technology Award.

1. Lu Z, Wang J, Shu Y, … Shen L*. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15). BMJ. 2022; 377:e068714. IF 105.7
2. Qi C, Gong J, Li J, … Shen L*. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine. 2022; 28(6):1189–1198. IF 82.9
3. Shen L#*, Kato K, Kim SB, … Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302). J Clin Oncol. 2022; 40(26):3065–3076. IF 45.3